Alpine Immune Sciences Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.03
Dividend & YieldN/A$ (N/A)
Beta 1.39
Market capitalization 283.75M
Operating cash flow -41.7M
ESG Scores unknown

Company description

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio2.75
Working Capital-0.41
Return On Equity-0.42
Debt To Equity0.03
Fixed Asset Ratio0.69
Fixed Interest Cover-61.1

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 4.91M 2.25M 51.05M 30.6M
Total Cashflows From Investing Activities 32.12M 16.76M -72.82M -52.48M
Net Borrowings -1M 644k 5M -2.4M
Total Cash From Financing Activities -991k 24.25M 61.38M 100.76M
Change To Operating Activities 66k 950k 1.89M -3.34M
Issuance Of Stock 9k 23.61M 56.38M 103.16M
Net Income -36.49M -41.85M -27.94M -50.33M
Change In Cash 2.71M 5.67M 18.7M 32.95M
Effect Of Exchange Rate -6k -6k 58k -88k
Total Cash From Operating Activities -28.42M -35.35M 30.08M -15.25M
Depreciation 388k 468k 578k 620k
Change To Account Receivables
Other Cashflows From Financing Activities
Change To Netincome 2.71M 2.84M 4.51M 7.21M
Capital Expenditures -495k -821k -802k -118k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -36.85M -41.85M -27.95M -50.42M
Net Income -36.49M -41.85M -27.94M -50.33M
Selling General Administrative 8.36M 9.47M 10.9M 14.56M
Gross Profit -28.27M -34.11M -17.85M -35.3M
Ebit -36.63M -43.57M -28.75M -49.86M
Operating Income -36.63M -43.57M -28.75M -49.86M
Interest Expense -319k -338k -775k -816k
Income Tax Expense -366k -6k -87k
Total Revenue 705k 1.74M 9.34M 23.44M
Cost Of Revenue 28.97M 35.85M 27.18M 58.74M
Total Other Income ExpenseNet -226k 1.72M 803k -561k
Net Income From Continuing Ops -36.49M -41.85M -27.94M -50.33M
Net Income Applicable To Common Shares -36.49M -41.85M -27.94M -50.33M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 10.28M 24.62M 81.93M 135M
Total Stockholder Equity 44.59M 29.47M 62.16M 120.9M
Other Current Liabilities 86k 1.44M 31.63M 51.9M
Total Assets 54.87M 54.09M 144.09M 255.9M
Common Stock 14k 19k 24k 30k
Other Current Assets 560k 706k 517k 3.67M
Retained Earnings -46.07M -87.93M -115.87M -166.2M
Treasury Stock -13k 10k 53k -273k
Cash 10.71M 16.12M 34.96M 67.91M
Total Current Liabilities 8.13M 8.68M 41.17M 69.78M
Other Stockholder Equity -13k 10k 53k -273k
Property, Plant, and Equipment 1.2M 11.54M 11.19M 10.55M
Total Current Assets 53.55M 42.3M 107.1M 192.01M
Net Tangible Assets 44.59M 29.47M 62.16M 120.9M
Net Receivables 237k 686k 388k 25.32M
Accounts Payable 1.72M 1.54M 582k 3.35M


Insider Transactions

Here are the insider transactions of stock shares related to Alpine Immune Sciences Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
CUI XIANGMINStock Award(Grant) at price 7.35 per share.I2022-09-23Director and Beneficial Owner of more than 10% of a Class of Security2M
DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P.Stock Award(Grant) at price 7.35 per share.I2022-09-23Beneficial Owner of more than 10% of a Class of Security2M
VENKATESAN JAY R M.D.Conversion of Exercise of derivative security at price 0.45 per share.D2022-07-15Director and Beneficial Owner of more than 10% of a Class of Security20.06k
FRAZIER LIFE SCIENCES VIII, L.P.Purchase at price 7.10 per share.I2022-02-11Beneficial Owner of more than 10% of a Class of Security112.67k
RICKEY JAMES PAULSale at price 13.92 per share.D2021-12-31Chief Financial Officer17.01k
CONWAY ROBERT EPurchase at price 10.08 per share.I2021-09-23Director15k
PEETZ CHRISTOPHERPurchase at price 10.17 per share.I2021-09-23Director1.9k
CONWAY ROBERT EPurchase at price 9.80 per share.I2021-09-21Director10k
GOLD MITCHELL HSale at price 9.40 - 10.01 per share.D/I2021-09-17Chief Executive Officer445.26k
ORBIMED ADVISORS, L.L.C.Purchase at price 9.40 per share.I2021-09-17Beneficial Owner of more than 10% of a Class of Security1.01M
THOMPSON PETER APurchase at price 9.40 per share.I2021-09-17Director and Beneficial Owner of more than 10% of a Class of Security1.01M
VENKATESAN JAY R M.D.Sale at price 9.40 per share.I2021-09-17Director and Beneficial Owner of more than 10% of a Class of Security400k
CUI XIANGMINPurchase at price 9.40 per share.I2021-09-17Director and Beneficial Owner of more than 10% of a Class of Security1.54M
ALPINE IMMUNOSCIENCES, L.P.Sale at price 9.40 per share.I2021-09-17Beneficial Owner of more than 10% of a Class of Security400k
DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P.Purchase at price 9.40 per share.I2021-09-17Beneficial Owner of more than 10% of a Class of Security1.54M
DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P.Purchase at price 9.40 per share.I2021-09-17Beneficial Owner of more than 10% of a Class of Security1.54M
GOLD MITCHELL HSale at price 10.00 per share.D2021-09-16Chief Executive Officer10.25k
GOLD MITCHELL HSale at price 10.00 - 10.01 per share.D2021-06-28Chief Executive Officer12.95k
GOLD MITCHELL HSale at price 15.00 - 15.03 per share.D2021-05-20Chief Executive Officer52.19k
GOLD MITCHELL HSale at price 11.52 - 11.68 per share.D2021-05-13Chief Executive Officer20k
GOLD MITCHELL HSale at price 10.07 - 10.52 per share.D2021-04-14Chief Executive Officer20k
VENKATESAN JAY R M.D.Conversion of Exercise of derivative security at price 3.62 - 4.09 per share.D2021-03-31Director and Beneficial Owner of more than 10% of a Class of Security15.3k
GOLD MITCHELL HSale at price 12.99 - 13.01 per share.D2021-03-05Chief Executive Officer20k
GOLD MITCHELL HSale at price 11.74 - 13.20 per share.D2021-02-02Chief Executive Officer20k
ORBIMED ADVISORS, L.L.C.Sale at price 14.25 per share.I2020-12-28Beneficial Owner of more than 10% of a Class of Security600k
THOMPSON PETER ASale at price 14.25 per share.I2020-12-28Director and Beneficial Owner of more than 10% of a Class of Security600k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Alpine Immune Sciences Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Alpine Immune Sciences Inc

Here is the result of two systematic investment strategies applied to Alpine Immune Sciences Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Alpine Immune Sciences Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Alpine Immune Sciences Inc:

Alpine Immune Sciences Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 159.66% on the backtest period.

Performance at glance

Performance

159.66 %

Latent gain

2787.75 $

Invested capital

1746.01 $

Annualized return

38.94 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Alpine Immune Sciences Inc

This is the result of two momentum investment strategies applied to Alpine Immune Sciences Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Alpine Immune Sciences Inc

The following chart shows all the entries opened by the momentum investment system on Alpine Immune Sciences Inc:

Alpine Immune Sciences Inc momentum entries
  • The first momentum investment strategy would give 146.66% of return on Alpine Immune Sciences Inc. That represents 7336.51$ of latent gain with 5002.53$ of employed capital.
  • The second momentum investment strategy would give 174.74% of return on Alpine Immune Sciences Inc. That represents 5668.79$ of latent gain with 3244.18$ of employed capital.
Performance at glance (1Q Momentum)

Performance

146.66 %

Latent gain

7336.51 $

Invested capital

5002.53 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

174.74 %

Latent gain

5668.79 $

Invested capital

3244.18 $

Annualized return

48.27 %

Momentum equity curve on Alpine Immune Sciences Inc

The following chart shows the equity curve of the two momentum strategies applied to Alpine Immune Sciences Inc:

Alpine Immune Sciences Inc momentum equity

Note: the dividends potentially given by Alpine Immune Sciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Alpine Immune Sciences Inc

The following chart shows the employed capital evolution of the two momentum strategies on Alpine Immune Sciences Inc since the beginning:

Alpine Immune Sciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Alpine Immune Sciences Inc

Buy the dip entry openings on Alpine Immune Sciences Inc

Alpine Immune Sciences Inc

The performance achieved by the robo-advisor on Alpine Immune Sciences Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Alpine Immune Sciences Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Alpine Immune Sciences Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Alpine Immune Sciences Inc

The following chart shows the result of the investment strategy applied to Alpine Immune Sciences Inc:

Alpine Immune Sciences Inc

Note: the dividends potentially given by Alpine Immune Sciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Alpine Immune Sciences Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Alpine Immune Sciences Inc:

Alpine Immune Sciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Alpine Immune Sciences Inc

In this section, I will compare the three previous investment strategies applied to Alpine Immune Sciences Inc.

Equity curve comparison on Alpine Immune Sciences Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Alpine Immune Sciences Inc investment strategy comparison

Employed capital comparison on Alpine Immune Sciences Inc

Alpine Immune Sciences Inc investment comparison

Performance comparison on Alpine Immune Sciences Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 159.66% 2787.75$ 1746.01$ 38.94%
Momentum 1 quarter 146.66% 7336.51$ 5002.53$ 37.99%
Momentum 2 quarters 174.74% 5668.79$ 3244.18$ 48.27%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

38.94 %

Momentum 1Q

48.27 %

Momentum 2Q

48.27 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Alpine Immune Sciences Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months


Note: The algorithm computes the probability of correlation between Alpine Immune Sciences Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Alpine Immune Sciences Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Alpine Immune Sciences Inc
Country United States
City Seattle
Address 188 East Blaine Street
Phone 206 788 4545
Website www.alpineimmunesciences.com
FullTime employees 85
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker ALPN
Market www.nasdaq.com

Alpine Immune Sciences Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown